ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee P. Tannenbaum Sells 2,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee P. Tannenbaum sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $63.87, for a total value of $127,740.00. Following the transaction, the director now owns 18,211 shares in the company, valued at $1,163,136.57. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

ANI Pharmaceuticals Trading Down 3.7 %

Shares of ANIP traded down $2.34 during trading hours on Friday, reaching $61.43. 153,427 shares of the company traded hands, compared to its average volume of 133,593. ANI Pharmaceuticals, Inc. has a 12 month low of $44.06 and a 12 month high of $70.81. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63. The company’s fifty day moving average price is $66.78 and its two-hundred day moving average price is $59.67. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 38.39 and a beta of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The business had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of ANIP. Texas Permanent School Fund Corp lifted its holdings in shares of ANI Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of ANI Pharmaceuticals by 0.9% in the 3rd quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after buying an additional 200 shares during the last quarter. California State Teachers Retirement System increased its position in ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 233 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in ANI Pharmaceuticals by 9.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 4,754 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 400 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of ANI Pharmaceuticals by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 4,447 shares of the specialty pharmaceutical company’s stock valued at $307,000 after purchasing an additional 404 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ANIP. Guggenheim restated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Capital One Financial began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Finally, HC Wainwright raised their target price on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Buy” and an average target price of $81.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.